Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
10.1007/s11684-020-0763-z
- Author:
Bin GU
1
;
Jianhong CHU
1
;
Depei WU
2
Author Information
1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology of Soochow University, Suzhou Institute of Blood and Marrow Transplantation, Suzhou, 215006, China.
2. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology of Soochow University, Suzhou Institute of Blood and Marrow Transplantation, Suzhou, 215006, China. wudepei@suda.edu.cn.
- Publication Type:Review
- Keywords:
CAR T;
acute myeloid leukemia;
immunotherapy
- MeSH:
Hematopoietic Stem Cell Transplantation;
Humans;
Immunotherapy, Adoptive;
Leukemia, Myeloid, Acute/therapy*;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Frontiers of Medicine
2020;14(6):701-710
- CountryChina
- Language:English
-
Abstract:
Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies. Relapse remains the main cause of treatment failure, especially for patients with intermediate or high risk stratification. Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect, which unfortunately puts the patient at risk of serious complications, such as graft-versus-host disease. Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease. In this review, we focus on the most recent and promising advances in CAR T therapies for AML.
